Oxford University Covid-19 vaccine trials resume

Grant Boone
September 12, 2020

In case of a mild side effect there are steps that could be taken, but in case of a major side effect, as in the case of the British drugmaker's vaccine trial, it was "normal procedure" to pause the testing, according to Swaminathan.

AstraZeneca announced on Wednesday it had "voluntarily paused" its trial of the vaccine developed alongside Oxford University after the volunteer developed an unexplained illness.

AstraZeneca has informed that the clinical trials for the coronavirus vaccine, AZD1222, developed along with Oxford University have resumed in the United Kingdom following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

What Happened: The WHO official said that the vaccine trial delay was good and a "wake-up call or a lesson for everyone to recognize the fact that there are ups and downs in research", CNBC reported Thursday. "It depends on a lot and we have to wait to see the details of what actually happened", she said. And capacity is also in place for an Australian vaccine being developed at The University of Queensland to be available in large numbers by mid-2021.

Diana Rigg, Emma Peel of 'The Avengers,' Dies at age 82
Tom Stoppard used to call her talent as "luminous" and definitely her demise would make everyone miss her down the line. Diana Rigg was an icon of the '60s and the news of her passing has reminded us how brilliant her career was.

"From what I understand a total of 8000 people in the [AstraZeneca trial] were either vaccinated with the new vaccine against Covid or they were injected with the meningococcal vaccine, and one person from the trial - we're told from unofficial sources - developed transverse myelitis, an inflammatory disease of the spinal cord".

"There is some linkage as a very rare occurrence between [transverse myelitis] and the meningococcal vaccine".

An independent committee will review the study's safety data before deciding whether the research will continue or not. He also said that early results are an indication that the vaccine is better placed, and safer than Russia's Sputnik V. The intranasal vaccine aims to promote a natural immune response to the coronavirus by combining the new virus' spike proteins with a weakened flu virus.

"So it may well be that a person who has had this vaccine was going to get transverse myelitis anyway and the two are not connected". In July, Abu Dhabi-based G42 Healthcare and Sinopharm initiated phase 3 trials in the UAE, Emirates News Agency (WAM) reported. "But the phase 3 trials are still in progress, it's still early and we haven't heard any ongoing results from them yet". And Doherty says numerous vaccines have the potential to be used together, which could offer an advantage to develop strong immunity quicker.

Other reports by

Discuss This Article